The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Azure Healthcare’s (AZV) subsidiary, Austco Canada, has been awarded a $1.6 million contract to supply its Tacera Nurse Call platform to a new 350 bed hospital
  • The contract was from building and construction company EllisDon who are building the hospital
  • Austco’s technology will be integrated with EllisDon’s technology which will enhance communication between patients and caregivers
  • The new hospital is expected to be completed in 2023
  • On market close for the day, Azure is down 3.23 per cent and is trading for 9 cents per share.

Azure Healthcare’s (AZV) subsidiary, Austco Canada, has received $1.6 million contract to supply its Tacera Nurse Call platform to a new 350 bed hospital.

The technology enables nurse call alarms to be monitored with alarm and response data then collected to measure the performance outcomes.

Austco Canada was picked by construction and building services company EllisDon as its software is the most flexible and advanced.

The new hospital is currently construction and is expected to be completed in 2023, with the Austco Tacera system expected to be delivered in 2022.

All beds will feature the Austco Patient System which will be integrated with EllisDon’s Building Management System. Both systems will enhance communication between patients and caregivers.

“We are committed to providing innovative solutions that deliver quality care and optimise the patient experience,” Austco CEO Clayton Astles said.

“Our exceptional Tacera nurse call system is integral to quality operation of any hospital and our technology drives productivity and ensures improvement in patient care,” he added.

On market close for the day, Azure is down 3.23 per cent and is trading for 9 cents per share.

AZV by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…